Identification

Name
Edoxaban
Accession Number
DB09075
Type
Small Molecule
Groups
Approved
Description

Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.

Structure
Thumb
Synonyms
Not Available
External IDs
DU 176 / DU 176b / DU-176 / DU-176b
Product Ingredients
IngredientUNIICASInChI Key
Edoxaban tosylate32W99UE810480449-71-6ZLFZITWZOYXXAW-QXXZOGQOSA-N
Edoxaban tosylate monohydrate972203R4EW1229194-11-9PSMMNJNZVZZNOI-SJILXJHISA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe, Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe, Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated15 mgOralDaiichi Sankyo Europe, Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe, Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe, Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe, Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated15 mgOralDaiichi Sankyo Europe, Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe, Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated30 mgOralDaiichi Sankyo Europe, Gmb H2015-06-19Not applicableEu
LixianaTablet, film coated60 mgOralDaiichi Sankyo Europe, Gmb H2015-06-19Not applicableEu
International/Other Brands
Lixiana (Daiichi-Sankyo)
Categories
UNII
NDU3J18APO
CAS number
480449-70-5
Weight
Average: 548.06
Monoisotopic: 547.1768513
Chemical Formula
C24H30ClN7O4S
InChI Key
HGVDHZBSSITLCT-JLJPHGGASA-N
InChI
InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t13-,15-,17+/m0/s1
IUPAC Name
N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-{5-methyl-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridine-2-amido}cyclohexyl]ethanediamide
SMILES
CN(C)C(=O)[[email protected]]1CC[[email protected]](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[[email protected]@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1

Pharmacology

Indication

Edoxaban is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.

Structured Indications
Pharmacodynamics

Administration of edoxaban results in prolongation of clotting time tests such as aPTT (activated partial thromboplastin time), PT (prothrombin time), and INR (international normalized ratio).

Mechanism of action

Edoxaban is a selective inhibitor of factor Xa, a serine endopeptidase of the clotting cascade required for cleavage of prothrombin into thrombin.

TargetActionsOrganism
ACoagulation factor X
inhibitor
Human
Absorption

Following oral administration, peak plasma edoxaban concentrations are observed within 1-2 hours. Absolute bioavailability is 62%.

Volume of distribution

The steady state volume of distribution is 107 L.

Protein binding

In vitro plasma protein binding is ~55%.

Metabolism

Edoxaban is not extensively metabolized by CYP3A4 resulting in minimal drug-drug interactions. However, it does interact with drugs that inhibit p-gp (p-glycoprotein), which is used to transport edoxaban across the intestinal wall. Unchanged edoxaban is the predominant form in plasma. There is minimal metabolism via hydrolysis (mediated by carboxylesterase 1), conjugation, and oxidation by CYP3A4. The predominant metabolite M-4, formed by hydrolysis, is human-specific and active and reaches less than 10% of the exposure of the parent compound in healthy subjects. Exposure to the other metabolites is less than 5% of exposure to edoxaban.

Route of elimination

Edoxaban is eliminated primarily as unchanged drug in urine. Renal clearance (11 L/hour) accounts for approximately 50% of the total clearance of edoxaban (22 L/hour). Metabolism and biliary/intestinal excretion account for the remaining clearance.

Half life

The terminal elimination half-life of edoxaban following oral administration is 10 to 14 hours.

Clearance

22 L/hr

Toxicity

Premature discontinuation of any oral anticoagulant, including edoxaban, in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If edoxaban is discontinued for reasons other than pathological bleeding or completion of a course of therapy, consider the use of another anticoagulant. Edoxaban increases the risk of potentially fatal major bleeding such as intracranial hemorrhage and gastrointestinal bleeding. Patients should be educated on how to watch for signs of major and minor bleeding and when to seek medical help. Co-administration of other anti-coagulants, anti-platelets, or thrombolytics may increase the risk of bleeding and should therefore be avoided.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Edoxaban.Approved, Investigational
AbciximabEdoxaban may increase the anticoagulant activities of Abciximab.Approved
AbemaciclibThe serum concentration of Edoxaban can be increased when it is combined with Abemaciclib.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Edoxaban.Approved, Investigational
AcemetacinAcemetacin may increase the anticoagulant activities of Edoxaban.Approved
AcenocoumarolEdoxaban may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Edoxaban can be increased when it is combined with Acetaminophen.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Edoxaban.Approved
AfatinibThe serum concentration of Edoxaban can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Edoxaban can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Edoxaban.Approved, Withdrawn
AlectinibThe serum concentration of Edoxaban can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Edoxaban can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Edoxaban.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Edoxaban.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Edoxaban.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Edoxaban.Approved, Illicit, Investigational
AlprostadilAlprostadil may increase the anticoagulant activities of Edoxaban.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Edoxaban.Approved
AltrenogestThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Edoxaban.Investigational
AmantadineThe serum concentration of Edoxaban can be increased when it is combined with Amantadine.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Edoxaban.Experimental, Investigational
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Edoxaban.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of Edoxaban can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Edoxaban.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Edoxaban.Approved
AmiodaroneThe serum concentration of Edoxaban can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Edoxaban can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Edoxaban can be increased when it is combined with Amlodipine.Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Edoxaban.Approved
AmprenavirThe serum concentration of Edoxaban can be increased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Edoxaban can be increased when it is combined with Amsacrine.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Edoxaban.Approved
AncrodEdoxaban may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Edoxaban.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Edoxaban.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Edoxaban.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Edoxaban.Approved
Antithrombin III humanEdoxaban may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Edoxaban.Approved
ApocyninApocynin may increase the anticoagulant activities of Edoxaban.Investigational
ApremilastApremilast may increase the anticoagulant activities of Edoxaban.Approved, Investigational
ArdeparinEdoxaban may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanEdoxaban may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Edoxaban.Investigational
AstemizoleThe serum concentration of Edoxaban can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Edoxaban can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Edoxaban can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Edoxaban can be increased when it is combined with Atorvastatin.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Edoxaban.Withdrawn
AzelastineThe serum concentration of Edoxaban can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Edoxaban can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Edoxaban.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Edoxaban.Experimental
BecaplerminEdoxaban may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Edoxaban.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Edoxaban.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Edoxaban.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Edoxaban.Withdrawn
BenzocaineThe serum concentration of Edoxaban can be increased when it is combined with Benzocaine.Approved
BenzydamineBenzydamine may increase the anticoagulant activities of Edoxaban.Approved
BepridilThe serum concentration of Edoxaban can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostBeraprost may increase the anticoagulant activities of Edoxaban.Investigational
BevoniumBevonium may increase the anticoagulant activities of Edoxaban.Experimental
BiperidenThe serum concentration of Edoxaban can be increased when it is combined with Biperiden.Approved, Investigational
BivalirudinEdoxaban may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Edoxaban can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BosutinibThe serum concentration of Edoxaban can be increased when it is combined with Bosutinib.Approved
BrinaseBrinase may increase the anticoagulant activities of Edoxaban.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Edoxaban.Approved
BromocriptineThe serum concentration of Edoxaban can be increased when it is combined with Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the anticoagulant activities of Edoxaban.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Edoxaban.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Edoxaban.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Edoxaban.Experimental
BuprenorphineThe serum concentration of Edoxaban can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Edoxaban can be increased when it is combined with Buspirone.Approved, Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Edoxaban.Investigational
CabazitaxelThe serum concentration of Edoxaban can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Edoxaban.Approved
CaffeineThe serum concentration of Edoxaban can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Edoxaban can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Edoxaban can be increased when it is combined with Candesartan.Experimental
Candesartan cilexetilThe serum concentration of Edoxaban can be increased when it is combined with Candesartan cilexetil.Approved
CangrelorCangrelor may increase the anticoagulant activities of Edoxaban.Approved
CaptoprilThe serum concentration of Edoxaban can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Edoxaban can be increased when it is combined with Carbamazepine.Approved, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Edoxaban can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Edoxaban can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may increase the anticoagulant activities of Edoxaban.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Edoxaban.Approved, Investigational
CertoparinEdoxaban may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe serum concentration of Edoxaban can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Edoxaban.Investigational, Withdrawn
ChlorpromazineThe serum concentration of Edoxaban can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Edoxaban can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Edoxaban can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholesterolThe serum concentration of Edoxaban can be increased when it is combined with Cholesterol.Experimental, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Edoxaban.Approved
CilazaprilThe serum concentration of Edoxaban can be increased when it is combined with Cilazapril.Approved
CilostazolCilostazol may increase the anticoagulant activities of Edoxaban.Approved
CimetidineThe serum concentration of Edoxaban can be increased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Edoxaban can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Edoxaban.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Edoxaban can be increased when it is combined with Citalopram.Approved
Citric AcidEdoxaban may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Edoxaban can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe serum concentration of Edoxaban can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Edoxaban can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Edoxaban.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Edoxaban.Approved, Nutraceutical
CloricromenCloricromen may increase the anticoagulant activities of Edoxaban.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Edoxaban.Experimental
ClotrimazoleThe serum concentration of Edoxaban can be increased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Edoxaban can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Edoxaban can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Edoxaban can be increased when it is combined with Colforsin.Experimental, Investigational
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Edoxaban is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Edoxaban.Approved
CrizotinibThe serum concentration of Edoxaban can be increased when it is combined with Crizotinib.Approved
CurcuminCurcumin may increase the anticoagulant activities of Edoxaban.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Edoxaban.Approved
CyclophosphamideThe serum concentration of Edoxaban can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Edoxaban can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may increase the anticoagulant activities of Edoxaban.Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Edoxaban.Approved
DaclatasvirThe serum concentration of Edoxaban can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Edoxaban can be increased when it is combined with Dactinomycin.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Edoxaban.Experimental
DalteparinEdoxaban may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidEdoxaban may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanEdoxaban may increase the anticoagulant activities of Darexaban.Investigational
DasatinibThe serum concentration of Edoxaban can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Edoxaban can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Edoxaban is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Edoxaban.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Edoxaban.Approved
DemegestoneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Edoxaban is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Edoxaban.Investigational
DesipramineThe serum concentration of Edoxaban can be increased when it is combined with Desipramine.Approved
DesirudinEdoxaban may increase the anticoagulant activities of Desirudin.Approved
DesloratadineThe serum concentration of Edoxaban can be increased when it is combined with Desloratadine.Approved, Investigational
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Edoxaban.Investigational
DesogestrelThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Desogestrel.Approved
DexamethasoneThe serum concentration of Edoxaban can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextranEdoxaban may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Edoxaban may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Edoxaban may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Edoxaban may increase the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of Edoxaban can be increased when it is combined with Dextromethorphan.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Edoxaban.Experimental
DiclofenacThe serum concentration of Edoxaban can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolEdoxaban may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Edoxaban.Approved, Investigational
DienogestThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Edoxaban.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Edoxaban.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Edoxaban.Approved
DigoxinThe serum concentration of Edoxaban can be increased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Edoxaban can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Edoxaban can be increased when it is combined with Diltiazem.Approved
DiphenadioneDiphenadione may increase the anticoagulant activities of Edoxaban.Experimental
DipyridamoleThe serum concentration of Edoxaban can be increased when it is combined with Dipyridamole.Approved
DitazoleDitazole may increase the anticoagulant activities of Edoxaban.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Edoxaban.Approved
DoxazosinThe serum concentration of Edoxaban can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Edoxaban can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Edoxaban can be increased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Edoxaban can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Edoxaban can be increased when it is combined with Dronedarone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Edoxaban.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Edoxaban.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Edoxaban.Investigational
DydrogesteroneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Edoxaban.Approved
E-6201E-6201 may increase the anticoagulant activities of Edoxaban.Investigational
Edetic AcidEdoxaban may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EnalaprilThe serum concentration of Edoxaban can be increased when it is combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Edoxaban can be increased when it is combined with Enasidenib.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Edoxaban.Approved, Investigational
EnoxaparinEdoxaban may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Edoxaban can be increased when it is combined with Enzalutamide.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Edoxaban.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Edoxaban.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Edoxaban.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Edoxaban.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Edoxaban.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Edoxaban.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Edoxaban.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Edoxaban.Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Edoxaban.Approved
ErgonovineThe serum concentration of Edoxaban can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Edoxaban can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Edoxaban can be increased when it is combined with Erythromycin.Approved, Vet Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Edoxaban.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Edoxaban.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Edoxaban can be increased when it is combined with Estramustine.Approved
EstriolEstriol may decrease the anticoagulant activities of Edoxaban.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Edoxaban.Approved
EstroneEstrone may decrease the anticoagulant activities of Edoxaban.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Edoxaban.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Edoxaban.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Edoxaban.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Edoxaban.Approved
Ethyl biscoumacetateEdoxaban may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthynodiolThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Ethynodiol.Experimental
EtodolacEtodolac may increase the anticoagulant activities of Edoxaban.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Edoxaban.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoposideThe serum concentration of Edoxaban can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may increase the anticoagulant activities of Edoxaban.Approved, Investigational
EtravirineThe serum concentration of Edoxaban can be increased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Edoxaban.Approved, Investigational
exisulindexisulind may increase the anticoagulant activities of Edoxaban.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Edoxaban.Experimental
FelodipineThe serum concentration of Edoxaban can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the anticoagulant activities of Edoxaban.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Edoxaban.Approved
FentanylThe serum concentration of Edoxaban can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may increase the anticoagulant activities of Edoxaban.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Edoxaban.Experimental
Ferulic acidEdoxaban may increase the anticoagulant activities of Ferulic acid.Experimental
FexofenadineThe serum concentration of Edoxaban can be increased when it is combined with Fexofenadine.Approved
FibrinolysinFibrinolysin may increase the anticoagulant activities of Edoxaban.Investigational
FidaxomicinThe serum concentration of Edoxaban can be increased when it is combined with Fidaxomicin.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Edoxaban.Approved, Withdrawn
FluconazoleThe serum concentration of Edoxaban can be increased when it is combined with Fluconazole.Approved
FluindioneEdoxaban may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Edoxaban.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Edoxaban.Experimental
FluoxetineThe serum concentration of Edoxaban can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Edoxaban can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Edoxaban can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Edoxaban can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Edoxaban.Approved, Investigational
FluvoxamineThe serum concentration of Edoxaban can be increased when it is combined with Fluvoxamine.Approved, Investigational
FondaparinuxEdoxaban may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumEdoxaban may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateEdoxaban may increase the anticoagulant activities of Gabexate.Investigational
GarlicThe serum concentration of Edoxaban can be decreased when it is combined with Garlic.Approved
GefitinibThe serum concentration of Edoxaban can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Edoxaban can be increased when it is combined with Genistein.Investigational
GestodeneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Gestrinone.Approved
GlecaprevirThe serum concentration of Edoxaban can be increased when it is combined with Glecaprevir.Approved
GlyburideThe serum concentration of Edoxaban can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Edoxaban can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Edoxaban can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Edoxaban can be increased when it is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalGuacetisal may increase the anticoagulant activities of Edoxaban.Experimental
HaloperidolThe serum concentration of Edoxaban can be increased when it is combined with Haloperidol.Approved
HeminHemin may increase the anticoagulant activities of Edoxaban.Approved
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Edoxaban.Experimental
HeparinEdoxaban may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Edoxaban.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Edoxaban.Investigational
HydrocortisoneThe serum concentration of Edoxaban can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Edoxaban.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Edoxaban is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Edoxaban.Approved
IbudilastIbudilast may increase the anticoagulant activities of Edoxaban.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Edoxaban.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Edoxaban.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Edoxaban.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Edoxaban.Approved, Nutraceutical
IdelalisibThe serum concentration of Edoxaban can be increased when it is combined with Idelalisib.Approved
IdraparinuxEdoxaban may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Edoxaban.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Edoxaban.Investigational
IloprostIloprost may increase the anticoagulant activities of Edoxaban.Approved, Investigational
ImatinibThe serum concentration of Edoxaban can be increased when it is combined with Imatinib.Approved
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Edoxaban.Experimental
ImipramineThe serum concentration of Edoxaban can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Edoxaban can be increased when it is combined with Indinavir.Approved
IndobufenIndobufen may increase the anticoagulant activities of Edoxaban.Investigational
IndomethacinThe serum concentration of Edoxaban can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Edoxaban.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Edoxaban.Experimental
IsavuconazoniumThe serum concentration of Edoxaban can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Edoxaban.Withdrawn
ItraconazoleThe serum concentration of Edoxaban can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Edoxaban can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Edoxaban can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneKebuzone may increase the anticoagulant activities of Edoxaban.Experimental
KetamineThe serum concentration of Edoxaban can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinKetanserin may increase the anticoagulant activities of Edoxaban.Investigational
KetoconazoleThe serum concentration of Edoxaban can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Edoxaban.Approved
LansoprazoleThe serum concentration of Edoxaban can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Edoxaban can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideLeflunomide may increase the anticoagulant activities of Edoxaban.Approved, Investigational
LepirudinEdoxaban may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanEdoxaban may increase the anticoagulant activities of Letaxaban.Investigational
LetermovirThe serum concentration of Edoxaban can be increased when it is combined with Letermovir.Approved
LevofloxacinThe serum concentration of Edoxaban can be increased when it is combined with Levofloxacin.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LidocaineThe serum concentration of Edoxaban can be increased when it is combined with Lidocaine.Approved, Vet Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Edoxaban.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Edoxaban.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Edoxaban.Investigational
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Edoxaban.Experimental
LomitapideThe serum concentration of Edoxaban can be increased when it is combined with Lomitapide.Approved
LonazolacLonazolac may increase the anticoagulant activities of Edoxaban.Experimental
LoperamideThe serum concentration of Edoxaban can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Edoxaban can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Edoxaban can be increased when it is combined with Loratadine.Approved
LornoxicamLornoxicam may increase the anticoagulant activities of Edoxaban.Approved, Investigational
LosartanThe serum concentration of Edoxaban can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Edoxaban can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Edoxaban.Approved, Investigational
LumacaftorThe serum concentration of Edoxaban can be increased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Edoxaban.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Edoxaban.Approved
MaprotilineThe serum concentration of Edoxaban can be increased when it is combined with Maprotiline.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Edoxaban.Approved, Investigational
MebendazoleThe serum concentration of Edoxaban can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Edoxaban.Approved
MefloquineThe serum concentration of Edoxaban can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Edoxaban can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelagatranEdoxaban may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
MeprobamateThe serum concentration of Edoxaban can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may increase the anticoagulant activities of Edoxaban.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Edoxaban.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Edoxaban.Investigational, Withdrawn
MethadoneThe serum concentration of Edoxaban can be increased when it is combined with Methadone.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Edoxaban.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Edoxaban.Approved
MethylestrenoloneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Methylestrenolone.Experimental
MetoprololThe serum concentration of Edoxaban can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Edoxaban can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Edoxaban can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Edoxaban can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Edoxaban can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Edoxaban.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Edoxaban.Approved
MitomycinThe serum concentration of Edoxaban can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Edoxaban can be increased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineMizoribine may increase the anticoagulant activities of Edoxaban.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Edoxaban.Experimental
MorphineThe serum concentration of Edoxaban can be increased when it is combined with Morphine.Approved, Investigational
MoxestrolMoxestrol may decrease the anticoagulant activities of Edoxaban.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Edoxaban.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Edoxaban.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Edoxaban.Approved
NadroparinEdoxaban may increase the anticoagulant activities of Nadroparin.Approved
NafamostatEdoxaban may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Edoxaban.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Edoxaban.Investigational
NaltrexoneThe serum concentration of Edoxaban can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenNaproxen may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
NaringeninThe serum concentration of Edoxaban can be increased when it is combined with Naringenin.Experimental
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Edoxaban.Approved, Withdrawn
NelfinavirThe serum concentration of Edoxaban can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Edoxaban can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Edoxaban.Approved
NicardipineThe serum concentration of Edoxaban can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Edoxaban can be increased when it is combined with Nifedipine.Approved
NifenazoneNifenazone may increase the anticoagulant activities of Edoxaban.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Edoxaban.Approved
NilotinibThe serum concentration of Edoxaban can be increased when it is combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the anticoagulant activities of Edoxaban.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Edoxaban is combined with Nintedanib.Approved
NisoldipineThe serum concentration of Edoxaban can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Edoxaban can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Edoxaban can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroaspirinNitroaspirin may increase the anticoagulant activities of Edoxaban.Investigational
NomegestrolThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Norgestrienone.Experimental
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Edoxaban.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Edoxaban is combined with Obinutuzumab.Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Edoxaban.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Edoxaban.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Edoxaban is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Edoxaban.Approved, Nutraceutical
OmeprazoleThe serum concentration of Edoxaban can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Edoxaban.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Edoxaban.Vet Approved
OtamixabanEdoxaban may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Edoxaban.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Edoxaban.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Edoxaban.Investigational
P-NitrophenolThe serum concentration of Edoxaban can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Edoxaban can be increased when it is combined with Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of Edoxaban can be increased when it is combined with Palmitic Acid.Approved, Experimental
PantoprazoleThe serum concentration of Edoxaban can be increased when it is combined with Pantoprazole.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Edoxaban.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Edoxaban.Approved, Investigational
ParoxetineThe serum concentration of Edoxaban can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Edoxaban.Investigational
Pentaerythritol TetranitrateEdoxaban may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Edoxaban.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Edoxaban.Approved, Investigational
PerindoprilThe serum concentration of Edoxaban can be increased when it is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Edoxaban is combined with Pethidine.Approved
PhenindioneEdoxaban may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonEdoxaban may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
PibrentasvirThe serum concentration of Edoxaban can be increased when it is combined with Pibrentasvir.Approved
PicotamidePicotamide may increase the anticoagulant activities of Edoxaban.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Edoxaban.Approved, Investigational
PimozideThe serum concentration of Edoxaban can be increased when it is combined with Pimozide.Approved
PirfenidonePirfenidone may increase the anticoagulant activities of Edoxaban.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Edoxaban.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Edoxaban.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Edoxaban.Approved
PonatinibThe serum concentration of Edoxaban can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Edoxaban can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Edoxaban.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Edoxaban.Approved
PravastatinThe serum concentration of Edoxaban can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Edoxaban can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Edoxaban can be increased when it is combined with Prednisone.Approved, Vet Approved
ProbenecidThe serum concentration of Edoxaban can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Edoxaban can be increased when it is combined with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Edoxaban.Experimental
PromegestoneThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Edoxaban.Investigational
PromethazineThe serum concentration of Edoxaban can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may increase the anticoagulant activities of Edoxaban.Approved, Investigational
PropafenoneThe serum concentration of Edoxaban can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Edoxaban can be increased when it is combined with Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Edoxaban.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Edoxaban.Experimental
Protein CEdoxaban may increase the anticoagulant activities of Protein C.Approved
Protein S humanEdoxaban may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEdoxaban may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Edoxaban can be increased when it is combined with Protriptyline.Approved
PTC299PTC299 may increase the anticoagulant activities of Edoxaban.Investigational
QuercetinThe serum concentration of Edoxaban can be increased when it is combined with Quercetin.Experimental, Investigational
QuinacrineThe serum concentration of Edoxaban can be increased when it is combined with Quinacrine.Approved, Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Edoxaban.Approved
QuinidineThe serum concentration of Edoxaban can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Edoxaban can be increased when it is combined with Quinine.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Edoxaban.Investigational
RanitidineThe serum concentration of Edoxaban can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Edoxaban can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Edoxaban can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Edoxaban can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Edoxaban can be increased when it is combined with Reserpine.Approved, Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Edoxaban.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Edoxaban.Approved
ReviparinEdoxaban may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Edoxaban.Approved
RifampicinThe serum concentration of Edoxaban can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Edoxaban can be increased when it is combined with Rilpivirine.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Edoxaban.Approved
RitonavirThe serum concentration of Edoxaban can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanEdoxaban may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Edoxaban.Investigational, Withdrawn
RolapitantThe serum concentration of Edoxaban can be increased when it is combined with Rolapitant.Approved
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Edoxaban.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Edoxaban.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Edoxaban.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Edoxaban.Approved
SaquinavirThe serum concentration of Edoxaban can be increased when it is combined with Saquinavir.Approved, Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Edoxaban.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Edoxaban.Experimental
ScopolamineThe serum concentration of Edoxaban can be increased when it is combined with Scopolamine.Approved
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Edoxaban.Investigational
SelegilineThe serum concentration of Edoxaban can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the anticoagulant activities of Edoxaban.Approved
SemapimodSemapimod may increase the anticoagulant activities of Edoxaban.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Edoxaban.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Edoxaban.Investigational
SertralineThe serum concentration of Edoxaban can be increased when it is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Edoxaban.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Edoxaban.Approved, Investigational
SimeprevirThe serum concentration of Edoxaban can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Edoxaban can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Edoxaban can be increased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Edoxaban can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Edoxaban can be increased when it is combined with Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Edoxaban.Investigational
St. John's WortThe metabolism of Edoxaban can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StaurosporineThe serum concentration of Edoxaban can be increased when it is combined with Staurosporine.Experimental
StreptokinaseStreptokinase may increase the anticoagulant activities of Edoxaban.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Edoxaban.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Edoxaban.Approved
SulfinpyrazoneThe serum concentration of Edoxaban can be increased when it is combined with Sulfinpyrazone.Approved
SulindacSulindac may increase the anticoagulant activities of Edoxaban.Approved
SulodexideEdoxaban may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe serum concentration of Edoxaban can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Edoxaban can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Edoxaban.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Edoxaban.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Edoxaban.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Edoxaban.Approved
TacrineThe serum concentration of Edoxaban can be increased when it is combined with Tacrine.Investigational, Withdrawn
TacrolimusThe serum concentration of Edoxaban can be increased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Edoxaban can be increased when it is combined with Tamoxifen.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Edoxaban.Investigational
Taurocholic AcidThe serum concentration of Edoxaban can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Edoxaban can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelmisartanThe serum concentration of Edoxaban can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Edoxaban can be increased when it is combined with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Edoxaban.Approved
TenidapTenidap may increase the anticoagulant activities of Edoxaban.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Edoxaban.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Edoxaban.Vet Approved
TerazosinThe serum concentration of Edoxaban can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Edoxaban can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideTeriflunomide may increase the anticoagulant activities of Edoxaban.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Edoxaban.Investigational
TestosteroneThe serum concentration of Edoxaban can be increased when it is combined with Testosterone.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Edoxaban.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Edoxaban.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Edoxaban.Approved
TiboloneTibolone may increase the anticoagulant activities of Edoxaban.Approved, Investigational
TicagrelorThe serum concentration of Edoxaban can be increased when it is combined with Ticagrelor.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Edoxaban.Approved
TinoridineTinoridine may increase the anticoagulant activities of Edoxaban.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Edoxaban.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Edoxaban.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Edoxaban.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Edoxaban.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Edoxaban.Approved
TolmetinTolmetin may increase the anticoagulant activities of Edoxaban.Approved
TolvaptanThe serum concentration of Edoxaban can be increased when it is combined with Tolvaptan.Approved
TositumomabThe risk or severity of adverse effects can be increased when Edoxaban is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Edoxaban.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Edoxaban.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Edoxaban.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Edoxaban.Approved
TribenosideTribenoside may increase the anticoagulant activities of Edoxaban.Experimental
TrifluoperazineThe serum concentration of Edoxaban can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Edoxaban can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TriflusalTriflusal may increase the anticoagulant activities of Edoxaban.Approved, Investigational
TrimethoprimThe serum concentration of Edoxaban can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Edoxaban can be increased when it is combined with Trimipramine.Approved
TriptolideTriptolide may increase the anticoagulant activities of Edoxaban.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Edoxaban.Approved
TroleandomycinThe serum concentration of Edoxaban can be increased when it is combined with Troleandomycin.Approved
TroxerutinEdoxaban may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Edoxaban.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Edoxaban.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Edoxaban.Approved, Investigational
VelpatasvirThe serum concentration of Edoxaban can be increased when it is combined with Velpatasvir.Approved
VenlafaxineThe serum concentration of Edoxaban can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Edoxaban can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Edoxaban can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Edoxaban can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Edoxaban can be increased when it is combined with Vinorelbine.Approved, Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Edoxaban.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Edoxaban.Approved
VoxilaprevirThe serum concentration of Edoxaban can be increased when it is combined with Voxilaprevir.Approved
WarfarinEdoxaban may increase the anticoagulant activities of Warfarin.Approved
XimelagatranEdoxaban may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Edoxaban.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Edoxaban.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Edoxaban.Approved
ZileutonZileuton may increase the anticoagulant activities of Edoxaban.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Edoxaban can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Edoxaban.Withdrawn
Food Interactions
Not Available

References

General References
  1. Turpie AG: New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008 Jan;29(2):155-65. Epub 2007 Dec 19. [PubMed:18096568]
  2. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S: Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010 Jul;50(7):743-53. doi: 10.1177/0091270009351883. Epub 2010 Jan 15. [PubMed:20081065]
  3. Yeh CH, Hogg K, Weitz JI: Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol. 2015 May;35(5):1056-65. doi: 10.1161/ATVBAHA.115.303397. Epub 2015 Mar 19. [PubMed:25792448]
  4. Senoo K, Lip GY: Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation. Semin Thromb Hemost. 2015 Mar;41(2):146-53. doi: 10.1055/s-0035-1544156. Epub 2015 Feb 15. [PubMed:25682085]
  5. Parasrampuria DA, Truitt KE: Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin Pharmacokinet. 2015 Nov 30. [PubMed:26620048]
External Links
KEGG Drug
D09546
PubChem Compound
10280735
PubChem Substance
310265005
ChemSpider
8456212
BindingDB
50328731
ChEBI
85973
ChEMBL
CHEMBL1269025
PharmGKB
PA166128806
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Edoxaban
AHFS Codes
  • 20:12.04.14 — Direct Factor Xa Inhibitors
FDA label
Download (600 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedSupportive CareHaemorrhage1
1CompletedTreatmentHaemorrhage1
1RecruitingBasic ScienceDeep Vein Thrombosis (DVT) / Venous Thromboembolism / Venous Thrombosis Pediatrics1
2CompletedOtherAnticoagulation Reversal / Healthy Volunteers1
2CompletedPreventionArthroplasty, Replacement, Hip / Deep Vein Thrombosis (DVT) / Embolism and Thrombosis / Thromboembolism / Thrombosis / Venous Thromboembolism1
2CompletedPreventionArthroplasty, Replacement, Hip / Thrombosis1
2CompletedPreventionDeep Vein Thrombosis (DVT) / Total Knee Arthroplasty (TKA) / Venous Thromboembolism1
2CompletedPreventionNonvalvular Atrial Fibrillation1
2CompletedPreventionNonvalvular Atrial Fibrillation / Strokes1
2CompletedPreventionNonvalvular Atrial Fibrillation / Thromboembolism1
2CompletedTreatmentDeep Vein Thrombosis (DVT) / Thrombosis, Venous1
2CompletedTreatmentPeripheral Arterial Disease (PAD)1
2RecruitingTreatmentHaemorrhage1
2, 3Unknown StatusTreatmentCerebral Infarctions / Strokes / Transient ischemia attacks1
3CompletedPreventionNon-valvular Atrial Fibrillation (NVAF)1
3CompletedPreventionNonvalvular Atrial Fibrillation / Strokes / Systemic Embolism1
3CompletedPreventionPrevention / Venous Thromboembolism1
3CompletedPreventionVenous Thromboembolism3
3CompletedTreatmentDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Thromboembolism / Thrombosis, Venous / Venous Thromboembolism1
3CompletedTreatmentNonvalvular Atrial Fibrillation1
3Not Yet RecruitingPreventionAtrial Flutter / Intracranial Hemorrhage, Hypertensive / Intracranial Hemorrhages / Intraventricular Hemorrhage / Microhaemorrhage / Nonvalvular Atrial Fibrillation / Small Vessel Cerebrovascular Disease / Subarachnoid Hemorrhage / Subdural haematoma1
3Not Yet RecruitingTreatmentMV(Mitral Valve) Repair1
3RecruitingPreventionAtrial High Rate Episodes1
3RecruitingPreventionNonvalvular Atrial Fibrillation1
3RecruitingTreatmentDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Venous Thromboembolism / Venous Thromboembolism (VTE)1
3RecruitingTreatmentNonvalvular Atrial Fibrillation3
4Active Not RecruitingTreatmentCoronary Artery Disease1
4CompletedTreatmentCancers / Deep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Venous Thromboembolism (VTE)1
4Not Yet RecruitingTreatmentLeft Atrial Appendage Closure / Non-valvular Atrial Fibrillation (NVAF)1
4RecruitingPreventionNonvalvular Atrial Fibrillation1
4RecruitingTreatmentDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism1
4RecruitingTreatmentDiabetes1
4TerminatedTreatmentNonvalvular Atrial Fibrillation1
Not AvailableActive Not RecruitingBasic ScienceNonvalvular Atrial Fibrillation1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableEnrolling by InvitationNot AvailableNonvalvular Atrial Fibrillation1
Not AvailableNot Yet RecruitingNot AvailableNonvalvular Atrial Fibrillation1
Not AvailableRecruitingNot AvailableAnticoagulants and Bleeding Disorders / Venous Thromboembolism1
Not AvailableRecruitingNot AvailableHeart Failure, Unspecified1
Not AvailableRecruitingNot AvailableNonvalvular Atrial Fibrillation3
Not AvailableRecruitingNot AvailableVenous Thromboembolism2
Not AvailableRecruitingTreatmentBlood Clots / Cancers / Deep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Venous Thromboembolism1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral15 mg
TabletOral30 mg
TabletOral60 mg
Tablet, film coatedOral15 mg
Tablet, film coatedOral30 mg
Tablet, film coatedOral60 mg
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral30 mg/1
Tablet, film coatedOral60 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US2013026553No2011-08-222031-08-22Us
US9149532No2008-03-282028-03-28Us
US7365205No2003-06-122023-06-12Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
pKa6.7FDA Label
Predicted Properties
PropertyValueSource
Water Solubility0.0114 mg/mLALOGPS
logP1.61ALOGPS
logP0.9ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)10.74ChemAxon
pKa (Strongest Basic)6.33ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area136.63 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity140.14 m3·mol-1ChemAxon
Polarizability56.31 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Gamma amino acids and derivatives
Alternative Parents
Alpha amino acid amides / 2-heteroaryl carboxamides / Thiazolecarboxamides / N-arylamides / Aralkylamines / Aryl chlorides / Imidolactams / Pyridines and derivatives / Tertiary carboxylic acid amides / Heteroaromatic compounds
show 8 more
Substituents
Alpha-amino acid amide / Gamma amino acid or derivatives / Alpha-amino acid or derivatives / 2-heteroaryl carboxamide / Thiazolecarboxamide / Thiazolecarboxylic acid or derivatives / N-arylamide / Aralkylamine / Aryl chloride / Aryl halide
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, monocarboxylic acid amide, chloropyridine, thiazolopyridine (CHEBI:85973)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
F10
Uniprot ID
P00742
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da
References
  1. Turpie AG: New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008 Jan;29(2):155-65. Epub 2007 Dec 19. [PubMed:18096568]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mikkaichi T, Yoshigae Y, Masumoto H, Imaoka T, Rozehnal V, Fischer T, Okudaira N, Izumi T: Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition. Drug Metab Dispos. 2014 Apr;42(4):520-8. doi: 10.1124/dmd.113.054866. Epub 2014 Jan 23. [PubMed:24459178]

Drug created on May 15, 2015 10:35 / Updated on November 23, 2017 11:19